The increased risk for colon cancer inpatients with ulcerative colitis relates to the severity and duration ofdisease; by suppressing inflammation in the colon, drugs such as thethiazolidinediones or other PPARγ agonists might play a role in colon cancerprevention. This evidence concerns the gene PPARG and malignant colon neoplasm.